Vetter Launches Vetter-Ject A New Syringe Closure System for Highly-Sensitive Compounds
Vetter has released of Vetter-Ject, a novel closure system for prefilled syringes. By this closure part a baked-in siliconization of an integrated needle syringe can be realized, which allows use in highly-sensitive compounds such as biologics. The tamper-evident closure system, combined with an integrated staked needle, supports the product integrity of Vetter-Ject. During the development of Vetter-Ject particular emphasis was laid on usability. The system has already earned two prestigious international prizes.
Pharmaceutical and biotech companies are increasingly developing drugs that incorporate sensitive and complex compounds. To best administer these drugs to the patient requires an injection system that can be used flexibly while being safe and simple to handle. Vetter-Ject is such a system. Consisting of a needle hub and a needle shield, the new syringe closure system is partly produced by means of a 2-component injection molding process of polypropylene and thermoplastic elastomer.
Individually Adaptable Siliconization
Due to the baked-in siliconization process for the glass barrel, less silicon oil than commonly used is necessary, making Vetter-Ject particularly suitable for silicon-sensitive drug products. The silicon content of the syringe can also be adjusted according to customer requirements. Thus, the amount of silicon used, as well as the related particle load, can be reduced by up to 80% when compared with the standard siliconization process applied to conventional syringe systems.
Safety and Convenience for the Patient
Vetter-Ject is ready-to-use with an integrated needle that is simple to handle and user-friendly. The tamper-evident closure enables that any attempt at opening of the closure system will be immediately and permanently visible to the naked eye. This product attribute is activated when the needle shield is removed and plastic bridges are broken, preventing any potential misuse or reuse. Vetter-Ject can be used with a wide range of primary packaging options such as different stoppers and glass barrels, which can be customized according to the needs of the drug product. Moreover Vetter provides complete sterile fill and finish services and offers as part of its packaging service the assembly and final packaging of Vetter-Ject syringe systems; from trays and plunger rod assembly, to auto-injector assembly and final packaging.
"Our patented syringe closure system offers pharmaceutical and biotech companies more options for filling highly sensitive parenteral drugs," says Tilman Roedle, Director Packaging Development at Vetter. "Patients and qualified medical personnel now have the advantage of the system's easy handling and high standards for product safety and integrity."
International Recognition
Recognizing its novel design, Vetter's new syringe closure system has already been the recipient of two international awards prior to its launch: the IF Design Award and the Red Dot Design Award. "The fact that two eminent juries recognize the novel attributes of Vetter-Ject, clearly demonstrates the full potential of our innovation," says Thomas Otto, Managing Director at Vetter.
Related News
-
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance